Global Equity Research
`
`Americas
`
`Pharmaceuticals
`
`Sector Comment
`
`
`
`
`
`26 November 2010
`www.ubs.com/investmentresearch
`
`Marc Goodman
`Analyst
`marc.goodman@ubs.com
`+1-212-713 1342
`Ami Fadia
`Analyst
`ami.fadia@ubs.com
`+1-212-713 3242
`Matthew Harrison
`Associate Analyst
`matthew.harrison@ubs.com
`+1 212 713 2429
`Leslie Velka
`Associate Analyst
`leslie.velka@ubs.com
`+1 212 713 3518
`
`
`
`
`
`
`
`ab
`
`UBS Investment Research
`U.S. Pharmaceuticals
`
`UBS Large Cap Pharmaceuticals
`Monthly Handbook
`
` What’s new? Issuing first edition of our large cap monthly
`This publication consists of monthly therapeutic market models along with
`market share estimates for key products and TRx growth trends. It also
`includes monthly promotion details tables for all the categories within large
`cap pharmaceuticals.
`
` (cid:132)
`
`(cid:132) Our takeaways for YTD2010 TRxs
`In anti-clotting, LLY’s Effient displayed steady growth from January
`through October while Bristol’s Plavix decelerated marginally. In CNS,
`FRX’s Savella continues to take market share from PFE’s Lyrica and has
`increased its share from 11.1% in January to 14.6% in October, while
`Lyrica has fallen from 53.0% to 47.5% in the same time frame. Also, PFE’s
`Effexor XR’s market share fell from 7.3% in June to 2.1% in October due
`to generic competition in July, which captured 6.0% of market share in
`October. In diabetes, BMY’s Onglyza continues to enjoy steady growth
`with market share increasing from 2.2% in January to 9.2% in October. In
`respiratory HFA, MRK’s Proventil continues to lose share to Glaxo’s
`Ventolin, dropping from 12.5% market share in January to 10.2% in
`October, wherein Ventolin market share increased from 27.8% to 35.2%.
`
`
`
`
`
`
`
`
`This report has been prepared by UBS Securities LLC
`ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 86.
`UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this
`report. Investors should consider this report as only a single factor in making their investment decision.
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1054 - Page 1
`
`

`
`U.S. Pharmaceuticals 26 November 2010
`
`Table 67: Urology – U.S. Overactive Bladder Annual
`
`
`2008
`
`2009
`
`2010E
`
`% of Total TRxs
`2011E
`2012E
`
`2013E
`
`2014E
`
`2015E
`
`2008
`
`2009
`
`2010E
`
`Total Sales ($ Millions)
`2011E
`2012E
`
`2013E
`
`2014E
`
`2015E
`
`Total Category Rxs ('000)
` Growth Rate
`
`Sanctura XR - Allergan
`Sanctura - Allergan
`Generic Sanctura (Trospium)
`Vesicare - GlaxoSmithKline
`Oxytrol - Watson
`Gelnique - Watson
`Enablex - Warner Chilcott
`Detrol LA - Pfizer
`Detrol - Pfizer
`Generic Detrol LA (Tolterodine)
`Ditropan XL - J&J
`Generic Ditropan XL (Oxybutynin)
`Ditropan - J&J
`Generic Ditropan (Oxybutynin)
`Urispas - J&J
`Generic Urispas (Flavoxate)
`Toviaz - Pfizer
`Others
`Total
`Growth Rate
`
`18,052
`3.6%
`
`1.4%
`1.8%
`0.0%
`14.6%
`1.9%
`0.0%
`9.0%
`36.0%
`2.6%
`0.0%
`0.7%
`15.9%
`0.0%
`15.5%
`0.0%
`0.6%
`0.0%
`0.0%
`100.0%
`
`18,500
`2.5%
`
`2.1%
`1.1%
`0.0%
`16.6%
`1.6%
`0.2%
`8.9%
`32.9%
`2.5%
`0.0%
`0.4%
`15.9%
`0.0%
`16.6%
`0.0%
`0.5%
`0.6%
`0.0%
`100.0%
`
`18,320
`-1.0%
`
`2.2%
`0.6%
`0.0%
`18.0%
`1.1%
`0.7%
`9.3%
`27.4%
`2.4%
`0.0%
`0.2%
`16.6%
`0.0%
`18.4%
`0.0%
`0.5%
`2.6%
`0.0%
`100.0%
`
`18,504
`1.0%
`
`2.3%
`0.0%
`0.3%
`18.9%
`0.8%
`0.8%
`9.3%
`24.9%
`2.0%
`0.0%
`0.1%
`17.8%
`0.0%
`18.8%
`0.0%
`0.2%
`3.6%
`0.0%
`100.0%
`
`18,689
`1.0%
`
`2.4%
`0.0%
`0.3%
`19.5%
`0.7%
`0.9%
`9.4%
`20.5%
`1.5%
`4.8%
`0.1%
`18.4%
`0.0%
`17.3%
`0.0%
`0.2%
`3.8%
`0.0%
`100.0%
`
`18,875
`1.0%
`
`2.5%
`0.0%
`0.3%
`19.7%
`0.5%
`1.1%
`9.5%
`2.1%
`0.9%
`24.6%
`0.1%
`18.4%
`0.0%
`16.4%
`0.0%
`0.2%
`3.8%
`0.0%
`100.0%
`
`19,064
`1.0%
`
`2.5%
`0.0%
`0.3%
`19.6%
`0.3%
`1.2%
`9.6%
`0.3%
`0.5%
`26.4%
`0.1%
`18.4%
`0.0%
`16.8%
`0.0%
`0.2%
`3.8%
`0.0%
`100.0%
`
`19,255
`1.0%
`
`2.5%
`0.0%
`0.3%
`19.6%
`0.2%
`1.3%
`9.7%
`0.3%
`0.5%
`26.4%
`0.1%
`18.4%
`0.0%
`16.7%
`0.0%
`0.2%
`3.8%
`0.0%
`100.0%
`
`Source: Company reports, IMS database and UBS estimates
`
`$33.8
`$34.8
`$0.0
`$131.4
`$36.0
`$0.0
`$170.9
`$756.2
`$65.8
`$0.0
`$17.2
`$150.6
`$0.4
`$7.0
`$0.3
`$4.3
`$0.0
`$0.0
`$1,408.7
`2.6%
`
`$41.3
`$24.4
`$0.0
`$162.0
`$33.5
`$7.4
`$196.1
`$756.2
`$64.9
`$0.0
`$10.5
`$149.3
`$0.0
`$8.2
`$0.0
`$4.2
`$10.8
`$0.0
`$1,469.0
`4.3%
`
`$46.4
`$13.5
`$0.3
`$171.1
`$23.8
`$12.9
`$212.8
`$655.3
`$64.6
`$0.0
`$7.1
`$139.3
`$0.1
`$8.4
`$0.0
`$4.0
`$54.7
`$0.0
`$1,414.3
`-3.7%
`
`$54.6
`$0.2
`$3.5
`$187.6
`$19.4
`$17.0
`$220.5
`$618.2
`$57.8
`$0.0
`$3.6
`$135.7
`$0.3
`$6.1
`$0.0
`$1.6
`$81.5
`$0.0
`$1,407.9
`-0.5%
`
`$61.5
`$0.0
`$3.5
`$201.4
`$16.5
`$20.7
`$231.8
`$530.7
`$45.4
`$12.5
`$3.7
`$127.2
`$0.3
`$4.0
`$0.0
`$1.6
`$93.5
`$0.0
`$1,354.5
`-3.8%
`
`$67.1
`$0.0
`$3.6
`$211.1
`$12.0
`$24.8
`$243.8
`$55.8
`$29.1
`$51.5
`$3.9
`$115.6
`$0.3
`$2.7
`$0.0
`$1.7
`$102.0
`$0.0
`$924.7
`-31.7%
`
`$72.2
`$0.0
`$3.6
`$218.8
`$7.9
`$29.2
`$256.3
`$7.5
`$17.2
`$41.9
`$4.0
`$105.1
`$0.4
`$1.9
`$0.0
`$1.7
`$111.3
`$0.0
`$878.8
`-5.0%
`
`$78.2
`$0.0
`$3.7
`$228.0
`$5.4
`$34.2
`$269.4
`$7.8
`$16.3
`$38.0
`$4.2
`$95.5
`$0.4
`$1.4
`$0.0
`$1.7
`$121.4
`$0.0
`$905.4
`3.0%
`
`
`
`
`
`
`
`UBS 70
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1054 - Page 2
`
`

`
`U.S. Pharmaceuticals 26 November 2010
`
`Table 68: Urology – U.S. Overactive Bladder Monthly
`
`2009
`18,499,967
`2.5%
`
`Jan-10
`1,514,738
`-2.0%
`
`Feb-10
`1,413,648
`-1.0%
`
`Mar-10
`1,614,480
`2.7%
`
`Apr-10
`1,518,844
`-1.0%
`
`May-10
`1,491,821
`-2.2%
`
`Jun-10
`1,559,797
`-0.2%
`
`Jul-10
`1,531,114
`-3.0%
`
`Aug-10
`1,546,620
`0.5%
`
`Sep-10
`1,511,659
`-2.2%
`
`Oct-10
`1,510,905
`-3.4%
`
`Nov-10E
`1,498,745
`0.0%
`
`2011E
`2010E
`Dec-10E
`1,607,949 18,320,320 18,503,523
`-1.0%
`1.0%
`0.0%
`
`Oct-10
`2.3%
`0.3%
`0.0%
`18.4%
`1.0%
`0.7%
`9.2%
`25.8%
`2.4%
`0.0%
`0.2%
`17.0%
`0.0%
`18.9%
`0.0%
`0.5%
`3.2%
`0.0%
`100.0%
`
`Nov-10E
`2.3%
`0.2%
`0.1%
`18.5%
`1.0%
`0.7%
`9.2%
`25.7%
`2.3%
`0.0%
`0.2%
`17.1%
`0.0%
`18.8%
`0.0%
`0.5%
`3.3%
`0.0%
`100.0%
`
`Dec-10E
`2.3%
`0.1%
`0.2%
`18.6%
`1.0%
`0.7%
`9.2%
`25.6%
`2.3%
`0.0%
`0.2%
`17.2%
`0.0%
`18.6%
`0.0%
`0.5%
`3.4%
`0.0%
`100.0%
`
`2010E
`2.2%
`0.6%
`0.0%
`18.0%
`1.1%
`0.7%
`9.3%
`27.4%
`2.4%
`0.0%
`0.2%
`16.6%
`0.0%
`18.4%
`0.0%
`0.5%
`2.6%
`0.0%
`100.0%
`
`2011E
`2.3%
`0.0%
`0.3%
`18.9%
`0.8%
`0.8%
`9.3%
`24.9%
`2.0%
`0.0%
`0.1%
`17.8%
`0.0%
`18.8%
`0.0%
`0.2%
`3.6%
`0.0%
`100.0%
`
`4Q10E
`
`2010E
`
`2011E
`
`1,295,026
`$158.6
`$122.46
`
`5,458,151
`$673.6
`$123.41
`
`4,979,304
`$609.8
`$122.46
`
`4Q10E
`
`2010E
`
`2011E
`
`152,976
`$17.5
`$114.68
`
`477,171
`$54.7
`$114.68
`
`669,855
`$81.5
`$121.67
`
`
`
`UBS 71
`
`
`Total Category Rx
`
`Market Share
`Sanctura XR - Allergan
`Sanctura - Allergan
`Generic Sanctura (Trospium)
`Vesicare - GlaxoSmithKline
`Oxytrol - Watson
`Gelnique - Watson
`Enablex - Warner Chilcott
`Detrol LA - Pfizer
`Detrol - Pfizer
`Generic Detrol LA (Tolterodine)
`Ditropan XL - J&J
`Generic Ditropan XL (Oxybutynin)
`Ditropan - J&J
`Generic Ditropan (Oxybutynin)
`Urispas - J&J
`Generic Urispas (Flavoxate)
`Toviaz - Pfizer
`Total Other
`Total
`
`Detrol/LA - Pfizer
`
` TRxs
` Sales
` Price/Rx
`
`Toviaz - Pfizer
`
` TRxs
` Sales
` Price/Rx
`
`Jan-10
`2.0%
`0.9%
`0.0%
`17.6%
`1.3%
`0.5%
`9.1%
`30.1%
`2.4%
`0.0%
`0.3%
`16.3%
`0.0%
`17.5%
`0.0%
`0.5%
`1.6%
`0.0%
`100.0%
`
`Feb-10
`2.0%
`0.9%
`0.0%
`17.5%
`1.2%
`0.6%
`9.2%
`29.4%
`2.4%
`0.0%
`0.3%
`16.4%
`0.0%
`17.9%
`0.0%
`0.5%
`1.8%
`0.0%
`100.0%
`
`Price Increase (1/1/2010):
`
`2009
`2.1%
`1.1%
`0.0%
`16.6%
`1.6%
`0.2%
`8.9%
`32.9%
`2.5%
`0.0%
`0.4%
`15.9%
`0.0%
`16.6%
`0.0%
`0.5%
`0.6%
`0.0%
`100.0%
`
`2009
`
`6,545,808
`$811.0
`$123.90
`
`2009
`
`109,319
`$10.8
`$114.68
`
`Mar-10
`2.0%
`0.9%
`0.0%
`17.6%
`1.2%
`0.6%
`9.3%
`28.8%
`2.4%
`0.0%
`0.3%
`16.4%
`0.0%
`18.1%
`0.0%
`0.5%
`2.0%
`0.0%
`100.0%
`
`1Q10A
`
`1,446,533
`$176.0
`$121.67
`5.0%
`1Q10A
`
`81,650
`$9.4
`$114.68
`
`Apr-10
`2.1%
`0.9%
`0.0%
`17.6%
`1.1%
`0.6%
`9.4%
`28.3%
`2.4%
`0.0%
`0.2%
`16.5%
`0.0%
`18.2%
`0.0%
`0.5%
`2.2%
`0.0%
`100.0%
`
`May-10
`2.1%
`0.8%
`0.0%
`17.6%
`1.1%
`0.7%
`9.5%
`27.9%
`2.4%
`0.0%
`0.2%
`16.5%
`0.0%
`18.2%
`0.0%
`0.5%
`2.4%
`0.0%
`100.0%
`
`Jul-10
`2.2%
`0.8%
`0.0%
`17.9%
`1.1%
`0.7%
`9.4%
`27.0%
`2.3%
`0.0%
`0.2%
`16.6%
`0.0%
`18.4%
`0.0%
`0.5%
`2.8%
`0.0%
`100.0%
`
`Aug-10
`2.2%
`0.7%
`0.0%
`18.0%
`1.0%
`0.7%
`9.4%
`26.6%
`2.3%
`0.0%
`0.2%
`16.7%
`0.0%
`18.6%
`0.0%
`0.5%
`3.0%
`0.0%
`100.0%
`
`Price Increase (7/1/2010):
`
`Jun-10
`2.1%
`0.8%
`0.0%
`17.8%
`1.1%
`0.7%
`9.5%
`27.6%
`2.4%
`0.0%
`0.2%
`16.4%
`0.0%
`18.3%
`0.0%
`0.5%
`2.6%
`0.0%
`100.0%
`
`2Q10A
`
`1,385,567
`$176.0
`$127.02
`
`2Q10A
`
`109,129
`$12.5
`$114.68
`
`Sep-10
`2.2%
`0.4%
`0.0%
`18.2%
`1.0%
`0.7%
`9.4%
`26.4%
`2.4%
`0.0%
`0.2%
`16.8%
`0.0%
`18.8%
`0.0%
`0.5%
`3.0%
`0.0%
`100.0%
`
`3Q10A
`
`1,331,025
`$163.0
`$122.46
`4.0%
`3Q10A
`
`133,416
`$15.3
`$114.68
`
`Source: Company reports, IMS database and UBS estimates
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1054 - Page 3
`
`

`
`U.S. Pharmaceuticals 26 November 2010
`
`Table 69: Urology – U.S. Overactive Bladder TRx Growth Rates
`
`TRx Growth rate
`Sanctura XR - Allergan
`Sanctura - Allergan
`Generic Sanctura (Trospium)
`Vesicare - GlaxoSmithKline
`Oxytrol - Watson
`Gelnique - Watson
`Enablex - Warner Chilcott
`Detrol LA - Pfizer
`Detrol - Pfizer
`Detrol Generic (Tolterodine)
`Generic Detrol LA (Tolterodine)
`Ditropan XL - J&J
`Generic Ditropan XL (Oxybutynin)
`Ditropan - J&J
`Generic Ditropan (Oxybutynin)
`Urispas - J&J
`Generic Urispas (Flavoxate)
`Toviaz - Pfizer
`Total Other
`Total
`
`2009
`56.9%
`-37.3%
`NM
`16.4%
`-15.0%
`NM
`2.1%
`-6.3%
`-2.4%
`0.0%
`NM
`-46.1%
`2.5%
`-79.9%
`9.8%
`-89.9%
`-3.5%
`NM
`NM
`2.5%
`
`Jan-10
`-8.7%
`-31.0%
`NM
`10.8%
`-30.6%
`NM
`-1.2%
`-15.3%
`-4.8%
`0.0%
`NM
`-42.3%
`0.5%
`-73.6%
`7.1%
`-95.8%
`-7.8%
`NM
`NM
`-2.0%
`
`Feb-10
`-11.3%
`-30.3%
`NM
`11.4%
`-33.0%
`NM
`1.0%
`-15.9%
`-3.2%
`0.0%
`NM
`-39.9%
`1.7%
`-58.9%
`9.7%
`-100.0%
`-4.0%
`NM
`NM
`-1.0%
`
`Mar-10
`-6.2%
`-29.5%
`NM
`14.1%
`-30.9%
`NM
`6.9%
`-13.9%
`-0.6%
`0.0%
`NM
`-35.8%
`5.8%
`-62.8%
`14.1%
`-94.7%
`0.5%
`NM
`NM
`2.7%
`
`Apr-10
`-7.3%
`-30.3%
`NM
`8.2%
`-34.1%
`NM
`4.2%
`-17.9%
`-5.9%
`0.0%
`NM
`-39.8%
`3.3%
`-57.7%
`10.3%
`-96.6%
`-6.4%
`NM
`NM
`-1.0%
`
`May-10
`-6.2%
`-30.8%
`NM
`5.6%
`-36.9%
`1981.1%
`3.8%
`-19.0%
`-7.5%
`0.0%
`NM
`-38.3%
`2.8%
`-42.9%
`8.5%
`-100.0%
`-6.0%
`NM
`NM
`-2.2%
`
`Jun-10
`-0.5%
`-28.0%
`NM
`7.6%
`-32.1%
`235.7%
`5.8%
`-17.4%
`-5.2%
`0.0%
`NM
`-34.5%
`3.8%
`-21.8%
`10.9%
`-71.4%
`-2.4%
`NM
`NM
`-0.2%
`
`Jul-10
`1.8%
`-30.6%
`NM
`4.3%
`-33.7%
`111.3%
`2.5%
`-20.1%
`-8.4%
`0.0%
`NM
`-38.3%
`1.8%
`-44.4%
`7.2%
`-100.0%
`-7.5%
`NM
`NM
`-3.0%
`
`Aug-10
`8.2%
`-32.3%
`NM
`7.0%
`-32.1%
`81.8%
`5.7%
`-17.2%
`-2.4%
`0.0%
`NM
`-31.0%
`4.8%
`-19.2%
`11.5%
`-33.3%
`-4.4%
`NM
`NM
`0.5%
`
`Sep-10
`6.0%
`-59.4%
`NM
`4.3%
`-34.4%
`57.9%
`3.5%
`-19.2%
`-5.6%
`0.0%
`NM
`-33.9%
`2.9%
`-2.4%
`8.6%
`-60.0%
`-5.8%
`NM
`NM
`-2.2%
`
`Oct-10
`8.3%
`-69.1%
`NM
`2.8%
`-33.6%
`42.5%
`0.8%
`-20.5%
`-6.1%
`0.0%
`NM
`-33.9%
`2.1%
`-52.3%
`6.8%
`-92.3%
`-9.2%
`NM
`NM
`-3.4%
`
`Nov-10E
`13.1%
`-78.0%
`NM
`5.8%
`-30.0%
`46.7%
`4.4%
`-17.0%
`-6.5%
`0.0%
`NM
`-28.1%
`6.3%
`-54.8%
`9.4%
`-75.2%
`-2.2%
`161.6%
`NM
`0.0%
`
`Dec-10E
`12.2%
`-87.8%
`NM
`5.0%
`-26.5%
`44.6%
`3.0%
`-16.6%
`-6.4%
`0.0%
`NM
`-28.2%
`7.9%
`-53.5%
`8.3%
`-92.4%
`-5.3%
`143.2%
`NM
`0.0%
`
`2010E
`0.6%
`-42.8%
`NM
`7.1%
`-32.4%
`170.6%
`3.4%
`-17.5%
`-5.2%
`0.0%
`NM
`-35.8%
`3.7%
`-51.2%
`9.3%
`-91.9%
`-5.1%
`336.5%
`NM
`-1.0%
`
`2011E
`10.0%
`-98.3%
`1077.4%
`6.5%
`-22.1%
`24.2%
`0.6%
`-8.4%
`-13.0%
`0.0%
`NM
`-50.8%
`8.3%
`461.8%
`3.2%
`-100.0%
`-59.6%
`40.4%
`1132.6%
`1.0%
`
`Source: Company reports, IMS database and UBS estimates
`
`
`
`
`
`UBS 72
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1054 - Page 4
`
`

`
`U.S. Pharmaceuticals 26 November 2010
`
`Table 70: Urology – U.S. Overactive Bladder Promotion Details Monthly
`
`# of Details for Tot. Category ('000s)
`Total Category
`Growth rate
`
`2008
`1,109
`-1.5%
`
`Market Share
`Sanctura XR - Allergan
`Sanctura - Allergan
`Vesicare - GlaxoSmithKline
`Oxytrol - Watson
`Gelnique - Watson
`Enablex - Warner Chilcott
`Detrol LA - Pfizer
`Detrol - Pfizer
`Toviaz - Pfizer
`Total
`
`2008
`9.7%
`1.0%
`31.5%
`5.2%
`0.0%
`18.6%
`32.5%
`1.5%
`0.0%
`100.0%
`Source: Company reports, IMS database and UBS estimates
`
`2009
`1,043
`-5.9%
`
`2009
`4.9%
`0.8%
`34.3%
`1.6%
`5.9%
`20.8%
`11.9%
`0.7%
`19.0%
`100.0%
`
`Jan-10
`98
`24.3%
`
`Jan-10
`6.6%
`2.2%
`37.3%
`0.0%
`7.2%
`14.9%
`2.4%
`0.0%
`29.5%
`100.0%
`
`Feb-10
`109
`28.8%
`
`Feb-10
`8.0%
`1.1%
`39.7%
`0.1%
`5.6%
`15.0%
`0.9%
`0.0%
`29.6%
`100.0%
`
`Mar-10
`112
`29.2%
`
`Mar-10
`5.9%
`1.4%
`37.3%
`0.0%
`7.5%
`13.6%
`1.0%
`0.1%
`33.1%
`100.0%
`
`Apr-10
`115
`24.8%
`
`Apr-10
`7.1%
`0.9%
`34.4%
`0.0%
`10.1%
`15.3%
`1.5%
`0.1%
`30.4%
`100.0%
`
`May-10
`100
`3.7%
`
`May-10
`6.5%
`1.5%
`33.4%
`0.2%
`8.6%
`15.9%
`0.7%
`0.3%
`32.8%
`100.0%
`
`Jun-10
`93
`-1.9%
`
`Jun-10
`9.0%
`2.0%
`33.0%
`0.0%
`11.0%
`13.9%
`1.3%
`0.2%
`29.5%
`100.0%
`
`Jul-10
`97
`3.1%
`
`Jul-10
`8.3%
`2.0%
`35.4%
`0.0%
`9.4%
`14.7%
`0.8%
`0.2%
`29.1%
`100.0%
`
`Aug-10
`97
`24.8%
`
`Aug-10
`9.1%
`1.7%
`33.2%
`0.3%
`9.9%
`15.0%
`0.9%
`0.2%
`29.7%
`100.0%
`
`Sep-10
`89
`-2.0%
`
`2010 YTD
`909
`14.3%
`
`Sep-10
`5.6%
`1.0%
`39.0%
`0.0%
`10.0%
`18.7%
`0.9%
`0.0%
`24.8%
`100.0%
`
`2010 YTD
`7.3%
`1.5%
`35.9%
`0.1%
`8.8%
`15.2%
`1.2%
`0.1%
`30.0%
`100.0%
`
`
`
`UBS 73
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1054 - Page 5